SARS-CoV-2 mRNA vaccine
Showing 1 - 25 of >10,000
SARS-CoV-2 Trial in Chengdu (SARS-CoV-2 mRNA vaccine (RBMRNA), CoronaVac®)
Active, not recruiting
- SARS-CoV-2
- SARS-CoV-2 mRNA vaccine (RBMRNA)
- CoronaVac®
-
Chengdu, Sichuan, ChinaChengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023
SARS-CoV-2 Trial in Chengdu (RBMRNA-176, Placebo)
Active, not recruiting
- SARS-CoV-2
- RBMRNA-176
- Placebo
-
Chengdu, Sichuan, ChinaChengdu Xinhua Hospital affiliated to North Sichuan Medical Coll
Jun 12, 2023
SARS-CoV-2 Trial (LVRNA009, 0.9%NaCl)
Not yet recruiting
- SARS-CoV-2
- LVRNA009
- 0.9%NaCl
- (no location specified)
Jan 11, 2023
SARS-CoV-2 Trial (SARS-CoV-2 mRNA Vaccine, Bivalent Low dose, SARS-CoV-2 mRNA Vaccine, Bivalent High dose, Placebo)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 mRNA Vaccine, Bivalent Low dose
- +2 more
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Jan 3, 2023
SARS-CoV-2, Safety, Immunotoxicity Trial in Wuhan (one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006), Cellular Immunity,
Not yet recruiting
- SARS-CoV-2
- +2 more
- one dose of the study SARS-CoV-2 mRNA Vaccine (SYS6006)
- +3 more
-
Wuhan, Hubei, ChinaZhongnan Hospital of Wuhan University
Aug 9, 2022
COVID-19 Trial in Nanjing, Hangzhou (20 µg dose of SYS6006, 30 µg dose of SYS6006, Placebo)
Enrolling by invitation
- SARS-CoV-2
- 20 μg dose of SYS6006 ;30 μg dose of SYS6006
- Placebo
-
Nanjing, Jiangsu, China
- +1 more
Dec 20, 2022
COVID-19 Trial in Nanjing, Hangzhou (20 µg dose of SYS6006, 30 µg dose of SYS6006, Placebo)
Enrolling by invitation
- SARS-CoV-2
- 20 μg dose of SYS6006;30 μg dose of SYS6006
- Placebo
-
Nanjing, Jiangsu, China
- +1 more
Dec 20, 2022
SARS-CoV-2 Trial in Islamabad (LVRNA009, CoronaVac®)
Not yet recruiting
- SARS-CoV-2
- LVRNA009
- CoronaVac®
-
Islamabad, PakistanClinical Trial Unit, National Institute of Health
Jun 22, 2022
COVID-19 Trial in Yuncheng, Hangzhou (Low-dose of LVRNA009, Middle-dose of LVRNA009, High-dose of LVRNA009)
Active, not recruiting
- COVID-19
- Low-dose of LVRNA009
- +3 more
-
Changsha, Hunan, China
- +2 more
Dec 1, 2022
SARS-CoV-2 Infection Trial in Shijia Zhuang (SYS6006)
Recruiting
- SARS-CoV-2 Infection
- SYS6006
-
Shijia Zhuang, Hebei, ChinaHebei Provincial Center For Disease Control and Prevention
Jul 4, 2022
SARS-CoV-2 Trial in Changsha, Xiangtan (SARS-CoV-2 (LVRNA009) 50µg group, SARS-CoV-2 (LVRNA009) 100µg group, Placebo)
Active, not recruiting
- SARS-CoV-2
- SARS-CoV-2 (LVRNA009) 50μg group
- +2 more
-
Changsha, Hunan, China
- +1 more
Jul 19, 2022
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
Recruiting
- SARS-CoV-2
- SPIKEVAX
-
New York, New YorkAetion, Inc
Nov 8, 2023
SARS-CoV-2 Trial in Jiangsu (BNT162b2, Placebo)
Completed
- SARS-CoV-2
- BNT162b2
- Placebo
-
Jiangsu, ChinaJiangsu Provincial Center for Disease Control and Prevention
May 9, 2022
SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Recombinant SARS-CoV-2 vaccine, Saline)
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA Vaccine
- +2 more
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023
SARS-CoV-2 Trial in Nanjing (SARS-CoV-2 Bivalent mRNA Vaccine, Saline)
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA Vaccine
- Saline
-
Nanjing, Jiangsu, ChinaJiangsu Provincial Center for Disease Control and Prevention
Jul 7, 2023
Chronic Lymphocytic Leukemia, COVID-19 Infection Trial in Duarte (Biospecimen Collection, mRNA COVID-19 Vaccine, Synthetic
Not yet recruiting
- Chronic Lymphocytic Leukemia
- COVID-19 Infection
- Biospecimen Collection
- +2 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023
IgG Antibodies After SARS-CoV-2 mRNA Vaccine in Kidney
Active, not recruiting
- Kidney Transplantation
- anti-spike SARS-CoV-2 IgG
-
Prague, CzechiaInstitute for Clinical and Experimental Medicine
Dec 16, 2021
COVID-19 Trial in Worldwide (SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA
Terminated
- COVID-19
- SARS-CoV-2 mRNA vaccine formulation 1
- +3 more
-
Rolling Hills Estates, California
- +20 more
Aug 22, 2022
SARS-CoV-2 Trial in Islamabad (SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021), 0.9% sodium chloride solution)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 Bivalent mRNA vaccine (LVRNA021)
- 0.9% sodium chloride solution
-
Islamabad, PakistanSindh Infectious Diseases Hospital & Research Center Dow Univers
Apr 16, 2023
SARS-CoV-2 Trial (SARS-CoV-2 variant mRNA vaccine low dose, SARS-CoV-2 variant mRNA vaccine high dose)
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 variant mRNA vaccine low dose
- SARS-CoV-2 variant mRNA vaccine high dose
- (no location specified)
Oct 30, 2022
Immunogenicity, Safety Trial (Phase II:SWIM816;SARS-Cov-2;, Phase II:SW-BIC-213;SARS-Cov-2;, PhaseIII:SWIM816;SARS-Cov-2;)
Not yet recruiting
- Immunogenicity
- Safety
- Phase II:SWIM816;SARS-Cov-2;
- +3 more
- (no location specified)
Jun 18, 2023
SARS-CoV-2 Trial (SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine high
Not yet recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA Vaccine low dose
- +2 more
- (no location specified)
Dec 1, 2022
SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose, SARS-CoV-2 Variant (Omicron BA.5) mRNA
Active, not recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine Low dose
- +2 more
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Jan 3, 2023
SARS-CoV-2 Trial in Bengbu (SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine, Saline solution)
Recruiting
- SARS-CoV-2
- SARS-CoV-2 Variant (Omicron BA.5) mRNA vaccine
- Saline solution
-
Bengbu, Anhui, ChinaFirst Affiliated Hospital Bengbu Medical College
Feb 26, 2023